Related Experiment Video
Updated: Jun 21, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Incidence and outcomes of malignant pediatric lung neoplasms
Holly L Neville1, Anthony R Hogan, Ying Zhuge
1Division of Pediatric Surgery and Division Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
Insights
Pediatric lung cancer incidence is stable, with endocrine tumors showing better survival. Non-surgical treatment and non-endocrine histology indicate a poor prognosis for these rare childhood cancers.
Area of Science:
- Pediatric Oncology
- Thoracic Surgery
- Epidemiology
Background:
- Lung and bronchus tumors are rare in children.
- Understanding current incidence and outcomes is crucial for pediatric cancer research.
Purpose of the Study:
- To define current incidence trends of pediatric lung and bronchus tumors.
- To analyze survival outcomes based on tumor type, treatment, and patient demographics.
Main Methods:
- Utilized the Surveillance, Epidemiology, and End Results (SEER) registry.
- Analyzed data from 1973 to 2004 for patients under 20 years old with pulmonary tumors.
Main Results:
- Identified 160 pediatric lung tumor cases; incidence remains stable at 0.049 per 100,000.
- Endocrine tumors (51.6%) showed the best survival, while small cell carcinoma had the worst.
- Surgical treatment significantly improved 10-year survival from 32% to 75% (P<0.0001).
Conclusions:
- Pediatric lung cancer incidence is stable, but prognosis varies significantly by histology.
- Non-surgical treatment and non-endocrine tumors are independent poor prognostic factors.
- Early diagnosis and surgical intervention are key to improving survival rates in pediatric lung cancer.
Background:
We sought to define current incidence trends and outcomes for children with lung and bronchus tumors.
Methods:
The SEER registry was queried from 1973 to 2004 for all patients with pulmonary tumors less than 20 y of age.
Results:
Overall, 160 patients were identified. The age-adjusted incidence has remained stable at 0.049 per 100,000 persons. The median age at diagnosis was 16 y. Whites had the highest age-adjusted population incidence at 0.056 per 100,000. Most tumors arose in the lower lobe (37%), followed by the upper lobe (31.2%). The most common histology was endocrine tumor (51.6%), followed by sarcoma (11%), and mucoepidermoid tumor (9%). Overall survival was greater than 381 mo with a 15-y survival of 65%. Males had better survival (>381 versus 288 months). Endocrine and mucoepidermoid tumors had the best survival. Small cell carcinoma had the worst median survival at less than 5 mo. Squamous cell carcinoma and adenocarcinoma both had a 14-mo median survival. Median survival for nonsurgically treated patients was 14 mo with a 10-y survival rate of 32%. Surgery improved the 10-y survival to 75% (P<0.0001). Multivariate analysis demonstrated nonsurgical treatment and nonendocrine tumor histology to be independent prognostic factors of death.
Conclusion:
The incidence of pediatric lung cancer remains stable. Several factors, including nonsurgical treatment and nonendocrine tumors confer a poor prognosis. Early diagnosis and surgical therapy provide the best chance for survival.